Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Blinded Extension Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of UCB0599 in Study Participants With Parkinson's Disease

NCT05543252 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT05543252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05543252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Blinded Extension Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of UCB0599 in Study Participants With Parkinson's Disease
Lead sponsor
UCB Biopharma SRL
Phase
Phase 2
Overall status
Terminated
Start date
August 29, 2022
Completion date
March 25, 2025
Enrollment
428 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease